Sunshine Biopharma, Inc.
SBFM
$1.05
$0.021.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.61% | 11.64% | 1.15% | 18.04% | 24.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.61% | 11.64% | 1.15% | 18.04% | 24.93% |
| Cost of Revenue | -14.67% | 13.91% | -13.81% | 18.98% | 27.18% |
| Gross Profit | -2.08% | 7.23% | 45.27% | 15.98% | 20.44% |
| SG&A Expenses | -8.72% | -12.20% | 34.85% | 8.07% | 70.48% |
| Depreciation & Amortization | 51.22% | 48.30% | 42.44% | 52.11% | 54.25% |
| Other Operating Expenses | 16.27% | 112.21% | -22.70% | 45.19% | 41.67% |
| Total Operating Expenses | -12.01% | 4.27% | -1.59% | 14.68% | 31.19% |
| Operating Income | 18.62% | 51.92% | 21.72% | 4.06% | -71.64% |
| Income Before Tax | 24.24% | -3.94% | -136.28% | 3.29% | -122.07% |
| Income Tax Expenses | 417.33% | -163.85% | 39.13% | -279.46% | -158.42% |
| Earnings from Continuing Operations | 0.80% | 26.21% | -258.24% | 8.10% | -72.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.80% | 26.21% | -258.24% | 8.10% | -72.66% |
| EBIT | 18.62% | 51.92% | 21.72% | 4.06% | -71.64% |
| EBITDA | 20.92% | 58.16% | 24.40% | 5.89% | -72.27% |
| EPS Basic | 56.03% | 79.47% | 96.04% | 78.20% | 98.83% |
| Normalized Basic EPS | 68.97% | 87.08% | 98.79% | 77.06% | 98.50% |
| EPS Diluted | 56.03% | 79.47% | 96.04% | 78.20% | 98.83% |
| Normalized Diluted EPS | 68.97% | 87.08% | 98.79% | 77.06% | 98.50% |
| Average Basic Shares Outstanding | 125.59% | 259.41% | 8,946.48% | 321.53% | 14,735.17% |
| Average Diluted Shares Outstanding | 125.59% | 259.41% | 8,946.48% | 321.53% | 14,735.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |